Director resignation Melbourne, Australia

Australia, September 24, 2021: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing

and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today received the resignation

of Mr Peter Anastasiou.

Anastasiou joined the Board in May 2015 after becoming a major shareholder in 2013 and was appointed Vice Executive Chairman in August

2015 to assist US market development opportunities and supporting key programs at Immuron.

Anastasiou commented that "Small companies rarely get an opportunity to acquire a transformative asset of national significance.

Our shareholders have lost a chance to contribute to the advancement of very safe Covid vaccine. As a result, I have decided to

step down despite my confidence in Immuron technology and the strong financial position the company is in".

Roger Aston said "The Board is enormously grateful to Peter for all of his hard work, energy and expertise over the last few years.

He has made a significant contribution in securing Immuron's long term future and leaves the Company in a substantially significantly

stronger position than when he joined the Board. The Company's strong cash reserves and pipeline of exciting projects promise a

bright future and we look forward to continuing our relationship with Peter in his capacity as a significant Shareholder".

Appendix 3Z for Mr Anastasiou is attached.

release has been authorised by directors of Immuron Limited.

Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered

targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron has a novel and safe technology

platform with one commercial asset generating revenue. In Australia, Travelan is a listed medicine on the Australian Register of

Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travellers' Diarrhea, reduce the risk of minor gastro-intestinal

disorders and is antimicrobial. In Canada, Travelan is a licenced natural health product (NPN 80046016) and is indicated to reduce

the risk of Travellers' Diarrhea. In the U.S., Travelan is sold as a dietary supplement for digestive tract protection in

accordance with section 403 (r)(6) of the Federal Drug Administration (FDA).

is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers' diarrhea,

a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce.

Travelan is a highly purified tabletized preparation of hyper immune bovine antibodies and other factors, which when taken with

meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers' diarrhea. In Australia,

Travelan is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk

of Travelers' Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan is

a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers' Diarrhea. In the U.S., Travelan

is sold as a dietary supplement for digestive tract protection.

diarrhea is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping,

bloating, and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic Escherichia coli (ETEC) playing

a dominant causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections

with Salmonella spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are

often confused with travelers' diarrhea as they may be contracted while travelling and initial symptoms are often indistinguishable.

more information visit: http://www.immuron.com

press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and

Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements

relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking

statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect

our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from

those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing

and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the

timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party

suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial

additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our

SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking

statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which

any such statement is based, except as required by law.

Final Director's Interest Notice

Director's Interest Notice

or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property

and may be made public.

(the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section

205G of the Corporations Act.

1 - Director's relevant interests in securities of which the director is the registered holder

the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director"

should be disclosed in this part.

Final Director's Interest Notice

2 - Director's relevant interests in securities of which the director is not the registered holder

In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director"

should be disclosed in this part.

the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

3 - Director's interests in contracts